- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01832701
Coffee, Exercise, and Oxidative Stress
Coffee and Oxidative Stress During Exercise in Healthy Humans
Panoramica dello studio
Descrizione dettagliata
Coffee is one of the most widely consumed beverages. It contains polyphenols (chlorogenic acids) and bioavailability of these bioactive compounds is now somewhat well understood. However, even if chlorogenic acids are known to be antioxidants in the cup, reliable evidence remains to be observed in vivo.
After medical examination and approval, subjects will undergo 2 periods of 21 days. The first 7 days will consist of a dietary restriction to lower the polyphenols intake. Then subjects will drink at random one of the three treatments for 14 days (4 cups/day). Blood and urine samples will be collected throughout the study to evaluate in vivo effects on oxidative biomarkers. Furthermore, at day 21, subjects will undergo a physical regimen to increase acutely and transiently their oxidative damage. Blood and urine samples collected throughout this challenge will allow us to evaluate the effect of coffee intake in reducing oxidative damage created by exercise compared to placebo.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Lausanne, Svizzera, 1000
- Clinical Development Unit / Metabolic Unit
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Healthy
- Normal and overweight subjects (BMI 19 - 29), with lean mass below the 90th percentile value
- Coffee drinkers with an average consumption of 1-3 cups per day
- Having given informed consent
- VO2 max as a function of age and gender, not higher than the values below:
Max oxygen uptake (VO2max, in ml/kg/min) in non athletes Age Males Females 20-29 49 41 30-39 47 39 40-49 45 37
Exclusion Criteria:
- Digestive (intestinal, gastric, hepatic or pancreatic), renal or metabolic disease, as determined by the medical (screening) visit and a blood chemistry analysis (glucose, cholesterol, LDL, HDL, triglycerides, aspartate transaminase (ASAT), Alanine transaminase (ALAT), C reactive Protein (CRP), creatinin)
Subjects at cardio-vascular risk rated as intermediate or high (according to the Swiss Society of Cardiology, lipids group (www.agla.ch/p11-1-2.html), meaning those who show at least one of the following criteria:
- History of coronary disease / atherosclerosis
- Diabetes
- High level of risk (familial hypercholesterolemia, hyperlipoproteinemia type III, hypertension)
- Metabolic syndrome defined by the presence of at least 3 out of the following criteria :
Abdominal circumference > 102 cm in men, > 88 cm in women Fasting triglycerides ≥ 1.7 mmol/l HDL-cholesterol < 1.0 mmol/l in men, < 1.3 mmol/l in women Systolic arterial blood pressure ≥ 130 mm Hg and/or diastolic arterial blood pressure ≥ 85 mm Hg Plasma glucose ≥ 6.1 mmol/l
- Anemia (Erythrocytes < 4.6 T/l (male) or < 4.2 T/l (women); Hemoglobin Hb < 13 g/dl (male) or Hb < 12 g/dl (women); Hematocrit Ht < 40% (male) or Ht < 37% (women); sera iron < 0.6 mg/l or plasma ferritin < 120 microg /l (male) or < 60 microg/l (non menopausal women)
- Troubles of hemostasis as determined by platelets number, prothrombin time and activated partial thromboplastin time
- Have had a gastrointestinal surgery, except appendicectomy
- Pregnancy
- History of food or medication allergy
- Have a regular consumption of medication (only those impacting oxidative stress biomarkers (eg. impacting the metabolism of lipids / LDL / VLDL), oral contraception excepted)
- Have taken antibiotic therapy within the last 3 months
- Smokers (more than 5 cigarettes per day)
- Having given blood within the last month, or willing to make a blood donation until one month following the end of the study
- Have a high alcohol consumption (more than 2 drinks/day)
- Taking more than 3 cups of coffee per day
- Consumption of illicit drugs
- Subject who cannot be expected to comply with the study procedures, including consuming the test products.
- Currently participating or having participated in another clinical trial during the last month prior to the beginning of this study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: coffee
4 cups of soluble coffee per day (2.5g per cup)
|
maltodextrine with caffeine
|
|
Comparatore placebo: Maltodextrine with caffeine
4 cups per day containing 2.5 g of product each
|
coffee versus placebo
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
oxidative stress
Lasso di tempo: Change in oxidative stress from baseline to the last day of a 14-day period of product intake
|
Oxidative stress will be assessed though urine beta-isoprostane measurements
|
Change in oxidative stress from baseline to the last day of a 14-day period of product intake
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Bioavailability of coffee antioxidative compounds
Lasso di tempo: Change in urine phenolic and chlorogenic acids from baseline to the last day of a 14-day period of product intake
|
Measures of phenolic and chlorogenic acids in urine
|
Change in urine phenolic and chlorogenic acids from baseline to the last day of a 14-day period of product intake
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Maurice Beaumont, MD, Clinical Development Unit / Metabolic Unit
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- 10.38.MET
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Placebo comparator
-
Beam Therapeutics Inc.ReclutamentoSoggetti sani | Studio di partecipanti saniRegno Unito
-
CHIA-HUI MAMackay Memorial HospitalCompletatoPazienti malati terminaliTaiwan
-
Beijing Tiantan HospitalReclutamentoEmorragia intracerebraleCina
-
Duke UniversityCompletatoLungo COVID | Lungo COVID-19 | Long Covid19Stati Uniti
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletatoLungo COVID | Lungo Covid19 | Lungo Covid-19Stati Uniti
-
Seoul National University Bundang HospitalChungnam National University HospitalTerminatoIctus | Emiplegia | Infarto sottocorticaleCorea del Sud
-
University of NottinghamCompletato
-
The Center for Clinical and Cosmetic ResearchRestore Biologics Holdings, LLC; Xtressé (TM)ReclutamentoDiradamento dei capelliStati Uniti
-
Namik Kemal UniversityIscrizione su invitoEducazione del paziente | Parto CesareoTurchia (Türkiye)
-
TeleflexReclutamentoCatetere centrale inserito perifericamenteCina